DuChemBIO Co.,Ltd. announced that it expects to receive KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.
September 23, 2020
Share
DuChemBIO Co.,Ltd. (XKON:A176750) announced a private placement of round 7 non-guaranteed private convertible bonds for gross proceeds of KRW 4,500,000,000 on September 23, 2020. The transaction will include participation from YNK Company Inc. for KRW 1,500,000,000 and RNR Partners for KRW 3,000,000,000. The bonds are fully convertible into 458,715 common shares of the company at conversion price of KRW 9,810 per share which represents 5.18% of the stake in the company. The conversion period starts at September 29, 2021 and ends at August 29, 2022. The maturity date of bonds is September 29, 2022. The payment date is September 29, 2020 and subscription date is September 23, 2020. The bonds will carry an interest rate of 6% and coupon rate of 4% in the transaction. The transaction has been approved by the board of directors of the company.
DuChemBio Co Ltd is a Korea-based company principally engaged in the manufacture and sale of radiopharmaceuticals. The Company is engaged in the manufacture and sale of diagnostic radiopharmaceuticals such as radiopharmaceuticals for the diagnosis of Parkinson's disease, radiopharmaceuticals for the diagnosis of Alzheimer's disease, and radiopharmaceuticals for the diagnosis of brain tumors. In addition, the Company is engaged in the sale of computed tomography (CT) contrast agents and other products.